EANS-Adhoc: Intercell AG / Intercell announces European approval of new vaccine, IXIARO®, to prevent Japanese Encephalitis

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

02.04.2009

» European Commission grants marketing authorization for Intercell´s
IXIARO®, the first licensed vaccine against Japanese Encephalitis
for travelers and military personnel in Europe

» This final decision follows the positive opinion from European
Committee for Human Medicinal Products (CHMP) in December 2008

Vienna (Austria), April 2, 2009 - Intercell AG (VSE: ICLL) today
announced that its new vaccine to prevent Japanese Encephalitis,
IXIARO®, has been approved by the European Commission. The approval
by the European Union, the first for a vaccine to prevent the
disease, provides formal market authorization in all 27 member states
as well as Norway and Iceland.

"The European approval of IXIARO marks a crucial milestone in
Intercell´s evolution as one of the leading independent vaccine
development companies with a vaccine marketed," said Intercell´s
Chief Executive Officer Gerd Zettlmeissl. "For the first time, both
civilians and members of the military across Europe will have access
to a safe and effective vaccine against this devastating and endemic
disease found throughout Asia, which kills as many as one in three of
the people it strikes."

This decision follows the positive opinion from European Committee
for Human Medicinal Products (CHMP) in December 2008. Novartis AG
holds marketing and distribution rights for IXIARO, in the United
States, Europe, Japan, Korea and certain other markets in Asia and
Latin America.

A final assessment by the European COMP (Committee for Orphan
Medicinal Products) focused on updated information indicating that
the expected potential European vaccine market for IXIARO is
significantly higher than initially evaluated, and, therefore, the
vaccine will not have an orphan drug designation.

Intercell's product is a purified, inactivated vaccine for active
immunization against infections with Japanese Encephalitis virus. The
new vaccine is manufactured in Intercell´s proprietary manufacturing
facility in Scotland and is prepared using tissue culture rather than
live organisms. In addition to the European approval, Intercell´s
vaccine was also approved by the Australian Therapeutic Goods
Administration (TGA) for use in Australia, and the U.S. Food and Drug
Administration for the U.S. market.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market